Request a Demo
Ziva Health›Health Guides›GLP-1 & Weight Loss Drugs
Health Guide · GLP-1 Drugs

GLP-1 changes far more
than the number
on the scale

Ozempic and Wegovy reduce appetite and drive weight loss - but they also improve HRV, reduce sleep apnea, lower resting heart rate, reduce cardiovascular risk by 20%, and shift metabolism in ways measurable in your wearable every night. Ziva tracks your full physiological response - not just the number on the scale.

How GLP-1 works Wearable response Cardiovascular Sleep Muscle loss risk Nutrition on GLP-1 Exercise Side effects How Ziva tracks Labs FAQ
Track your GLP-1 response Understand the science
Isabella · GLP-1 response — week 12
Semaglutide — week 12 of dose escalation
Strong response
HRV up 11 ms, RHR down 6 bpm, deep sleep improved. Resistance training adherence is protecting muscle - recovery score strong.
HRV — 12-week trend
52 ms ↑ 11 ms from baseline
Resting heart rate
64 bpm ↓ 6 bpm from week 1
Deep sleep
21% ↑ from 13% at baseline
Resistance training sessions
3× this week
"Your HRV improvement is ahead of the typical semaglutide response curve - your resistance training is likely protecting your lean mass and accelerating the metabolic benefit. Keep the protein intake high."
15%
Average weight loss with
semaglutide (Wegovy) over 68 weeks
20%
Reduction in cardiovascular events
(SELECT trial, non-diabetic adults)
HRV↑
Rises as insulin resistance improves
— measurable within 8–12 weeks
Sleep
Apnea events reduced by 50%+
in GLP-1 clinical trials
Muscle
25–40% of weight lost can be
lean mass without intervention
How GLP-1 Drugs Work

A gut hormone that
rewires appetite and metabolism

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the intestines after eating. It signals fullness to the brain, slows gastric emptying, stimulates insulin release, and suppresses glucagon. GLP-1 receptor agonist drugs - semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) - amplify these signals dramatically, producing sustained appetite suppression and significant metabolic changes.

These aren't simply appetite suppressants. Clinical trials show GLP-1 medications reduce cardiovascular event risk, significantly improve sleep apnea, lower blood pressure and inflammation, improve liver health, and - through all of these pathways - produce measurable improvements in HRV, resting heart rate, and sleep architecture that are visible in wearable data weeks before the scale fully reflects the metabolic shift.

Semaglutide — Ozempic / Wegovy
GLP-1 receptor agonist. Ozempic is approved for type 2 diabetes; Wegovy for obesity (BMI ≥30, or ≥27 with weight-related condition). Average weight loss: ~15% of body weight over 68 weeks in the STEP trials. Weekly subcutaneous injection, dose-escalated over 16–20 weeks.
Tirzepatide — Mounjaro / Zepbound
Dual GIP and GLP-1 receptor agonist - the newer, more potent class. Average weight loss: 20–22% in the SURMOUNT trials - meaningfully larger than semaglutide. Mounjaro approved for type 2 diabetes; Zepbound for obesity. Also weekly injection with dose escalation.
How they produce weight loss
GLP-1 agonists act on receptors in the hypothalamus - reducing appetite, increasing satiety, and shifting food preference away from hyper-palatable foods. Gastric emptying slows, prolonging fullness after meals. Appetite reduction averages 20–35% of caloric intake - producing weight loss through reduced energy intake without requiring willpower or conscious restriction.
GLP-1 — beyond appetite suppression
Brain
Appetite suppression, reduced food reward signals, craving reduction for ultra-processed foods
Heart
20% reduction in cardiovascular events, blood pressure reduction, inflammation reduction - HRV improves, RHR falls
Pancreas
Stimulates insulin release in response to meals, suppresses glucagon - lowers blood sugar and reduces insulin resistance
Sleep
Reduces sleep apnea severity by 50%+, improves deep sleep percentage, reduces overnight respiratory rate
Liver
Reduces hepatic fat, improves liver enzymes, reduces systemic inflammation - downstream HRV benefit
GLP-1 is not just for people with diabetes

The SELECT trial enrolled 17,604 adults with obesity but no diabetes - and found semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20%. This established GLP-1 agonists as a cardiovascular medication, not just a weight loss or diabetes drug. The cardiovascular benefit appears to be partly independent of weight loss, with anti-inflammatory and direct cardiac effects contributing to the outcome.

Wearable Response to GLP-1

Your wearable shows the response
weeks before the clinic does

HbA1c takes 3 months to reflect glycaemic improvement. Blood pressure labs require a clinic visit. But HRV, resting heart rate, sleep architecture, and activity tolerance respond to GLP-1's metabolic effects within weeks - providing continuous, real-time evidence of your physiological response between clinic appointments.

HRV — rising over weeks
Weeks 4–16
As insulin resistance improves, sympathetic nervous system overactivation reduces - directly raising HRV. As visceral fat decreases, systemic inflammation falls - HRV improves further. As sleep apnea burden reduces, overnight HRV quality improves. These three mechanisms compound: typical HRV improvement over 12 weeks of GLP-1 therapy is 8–15 ms - a clinically meaningful change in autonomic health.
Resting heart rate — falling
Weeks 2–8
Reduced cardiac workload as weight decreases, improved insulin sensitivity reducing sympathetic tone, and lower blood pressure all contribute to a falling resting heart rate. A drop of 4–8 bpm over 8–12 weeks is typical. Isabella tracks your RHR trend weekly and correlates it with logged medication, nutrition, and weight data.
Activity tolerance — improving
Weeks 4–12
Reduced body weight lowers the metabolic cost of movement - making the same physical activity easier and improving VO2 max proxy metrics. Heart rate at a given walking or cycling pace typically falls by 8–15 bpm over 12 weeks. Isabella tracks your exercise heart rate response over time as a proxy for improving cardiorespiratory fitness.
Recovery score — improving
Weeks 6–16
Wearable readiness and recovery scores improve as HRV rises, RHR falls, and sleep architecture normalises. The initial weeks of GLP-1 therapy - particularly during dose escalation with nausea - may temporarily suppress readiness scores as the body adjusts. Isabella contextualises these early fluctuations against the medium-term trend.
Typical wearable response timeline
Week 1–2
Nausea may reduce activity and suppress HRV temporarily. RHR unchanged. Sleep may slightly improve as appetite normalises.
Week 2–6
First HRV improvements emerge. RHR begins falling. Activity tolerance starts improving. Sleep apnea events begin reducing. Energy improving as blood sugar stabilises.
Week 6–16
Sustained HRV improvement (+8–15 ms). RHR down 4–8 bpm. Deep sleep improving. VO2 max proxy rising. Recovery scores at new high.
Month 6+
Full cardiovascular and metabolic benefit visible. HRV at new personal high. Sleep architecture normalised. Wearable data confirms sustained physiological response.
I
Isabella
GLP-1 response — week 10
On track
"Your wearable data is showing a clear GLP-1 response. HRV is up 9 ms and RHR is down 5 bpm over 10 weeks — both ahead of the typical response curve. Your sleep apnea signal (overnight respiratory rate variability) is also improving. One flag: on the 3 weeks you skipped resistance training, your recovery scores the following week were lower — muscle preservation should stay a priority at this phase of dose escalation."
+9 ms
HRV gain 10 weeks
−5 bpm
RHR reduction
+8%
deep sleep improvement
Cardiovascular Effects

GLP-1 is a cardiovascular drug
as much as a weight loss drug

The SELECT trial - the largest cardiovascular outcomes trial in obesity - found semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity but no diabetes over 3.3 years. This is a landmark result: it established GLP-1 agonists as cardiovascular medications, not just weight loss tools. The benefit appears to come from multiple pathways - some directly from weight loss, others from anti-inflammatory and direct cardiac effects independent of weight.

Blood pressure
−5 to −8 mmHg
systolic reduction in clinical trials
GLP-1 agonists produce significant blood pressure reduction through weight loss, improved insulin sensitivity, natriuresis, and direct vasodilatory effects. The blood pressure reduction correlates directly with wearable HRV improvement - Isabella tracks resting HR and recovery patterns as proxies for cardiovascular load.
Inflammation
hs-CRP↓
significant reduction in inflammatory markers
GLP-1 agonists reduce systemic inflammation - measurable as falling hs-CRP - through visceral fat reduction, improved glucose regulation, and direct anti-inflammatory effects on immune cells. Chronic inflammation is a primary HRV suppressant: as inflammation falls, HRV rises. This is one of the key mechanisms linking GLP-1 therapy to wearable HRV improvement.
Heart rate
−4–8 bpm
resting heart rate reduction — tracked daily in Ziva
Falling resting heart rate reflects reduced cardiac workload, improved autonomic tone, and lower sympathetic drive - all direct markers of improving cardiovascular health. GLP-1 drugs also have a slight chronotropic effect (may mildly raise HR acutely) that is typically offset by the sympatholytic effects of weight loss and insulin sensitisation over weeks.
HRV as cardiovascular response monitor
Improving HRV on GLP-1 therapy represents genuine cardiovascular benefit - not just a number. HRV is an independent predictor of cardiovascular events and mortality, and rising HRV reflects falling sympathetic overdrive, reduced inflammation, and improved autonomic cardiac regulation. A patient whose HRV rises from 32 ms to 45 ms over 12 weeks of GLP-1 therapy is demonstrably improving their cardiovascular risk profile in a way that a 3-monthly HbA1c or a clinic blood pressure reading doesn't capture continuously. Isabella presents this as a continuous cardiovascular health trajectory for your provider.
Sleep & GLP-1

One of the most under-reported
benefits - sleep transformation

Clinical trials of GLP-1 agonists show dramatic improvements in sleep apnea - one trial found a 50%+ reduction in apnea-hypopnea index with semaglutide over 12 months. Sleep apnea is common in people with obesity, suppresses HRV, fragments sleep architecture, and independently raises cardiovascular risk. As it resolves on GLP-1 therapy, the wearable effects are significant and measurable: deep sleep percentage rises, overnight HRV improves, and morning readiness scores climb.

Sleep apnea reduction
Upper airway anatomy improves as pharyngeal fat decreases. The SCALE Sleep trial found significant sleep apnea reduction with semaglutide. The wearable signature is a falling overnight respiratory rate variability - Isabella tracks this as a proxy for sleep apnea burden and correlates it with your deep sleep percentage and HRV over weeks.
Deep sleep architecture
Improved insulin sensitivity directly improves slow-wave sleep - insulin resistance and hyperglycaemia disrupt deep sleep architecture. As blood sugar stabilises on GLP-1 therapy, deep sleep percentage typically rises from baseline. This is one of the earliest and most consistent wearable improvements - often visible within 4–6 weeks.
Overnight HRV quality
Sleep apnea produces HRV fragmentation overnight - repeated micro-arousals prevent the sustained parasympathetic dominance needed for quality HRV recovery. As apnea burden reduces on GLP-1, overnight HRV improves in quality, not just average level. The wearable sees this as smoother, higher overnight HRV curves and better morning readiness scores.
If you use a CPAP — an important note
If you currently use CPAP for sleep apnea and start GLP-1 therapy, your sleep apnea severity may reduce significantly over 6–12 months. Your wearable data will show this before your next sleep study - Isabella flags consistent improvement in overnight respiratory patterns as a prompt to discuss CPAP pressure adjustment or potential discontinuation with your sleep physician.
Sleep improvement — typical GLP-1 trajectory
Nausea and sleep — the first weeks

During the dose escalation phase (weeks 1–16), nausea - GLP-1's most common side effect - can temporarily disrupt sleep onset and suppress HRV. Isabella distinguishes this expected early-phase pattern from sustained deterioration by contextualising HRV and sleep data against logged dose changes and nausea. The nausea effect typically resolves at each dose level within 2–4 weeks, after which the metabolic sleep benefits become visible.

The Muscle Loss Problem

25–40% of GLP-1 weight loss
can be lean mass - not just fat

Rapid caloric reduction on GLP-1 therapy creates a significant risk of lean muscle mass loss alongside fat loss - studies suggest 25–40% of the weight lost may be muscle without appropriate intervention. Muscle loss worsens insulin resistance, reduces metabolic rate (increasing rebound risk), impairs functional capacity, and reduces the long-term benefit of GLP-1 therapy. Preventing it requires resistance training and adequate protein intake - and Ziva tracks both.

Why muscle loss matters on GLP-1
Worsened insulin resistance - muscle is the largest glucose-disposal organ. Losing it reduces metabolic capacity and makes insulin resistance worse long-term.
Lower basal metabolic rate - less muscle = fewer calories burned at rest, increasing the risk of weight regain if GLP-1 is discontinued.
Functional decline - particularly relevant in older adults, where muscle loss accelerates sarcopenia and increases fall risk.
HRV impact - muscle mass supports cardiovascular fitness and metabolic health; losing it blunts the HRV improvement otherwise expected from GLP-1 therapy.
The wearable signal of muscle preservation

Maintaining resistance training while on GLP-1 therapy produces a measurably different HRV trajectory than weight loss alone - HRV rises faster and higher when lean mass is preserved, because muscle preservation protects insulin sensitivity and metabolic health. Isabella tracks your resistance training frequency and correlates it with your HRV improvement rate - making the muscle-protection benefit visible in objective data.

How to protect muscle on GLP-1
Protein — 1.6–2.2g per kg of body weight
Adequate protein is the most critical nutritional intervention for muscle preservation during GLP-1 therapy. Because overall caloric intake drops significantly, hitting protein targets requires intentional prioritisation - protein-first meal ordering, protein at every meal, and supplementation if needed. Log in Ziva Nutrition and Isabella tracks daily protein against your target.
Resistance training — 2–3× per week minimum
Progressive resistance training is the most effective stimulus for preserving lean mass during caloric deficit. Even 2 sessions per week significantly reduce lean mass loss compared to cardio-only approaches. Compound movements (squat, deadlift, press, row) stimulate the most muscle retention. Isabella tracks your training sessions and correlates frequency with HRV trajectory.
Don't cut calories too aggressively
GLP-1 dramatically reduces appetite - but eating too little too fast accelerates muscle loss. A deficit of 500–750 kcal/day is the evidence-based target for optimising fat loss while preserving lean mass. Very low calorie intake (below 1200–1400 kcal/day) should be avoided without medical supervision. Isabella tracks your logged intake and flags when it falls below muscle-preservation thresholds.
Creatine supplementation
Creatine monohydrate (5g/day) is the most evidence-backed supplement for lean mass preservation during caloric restriction. Multiple RCTs show it reduces lean mass loss during weight loss protocols. Safe, inexpensive, and well-tolerated. Log in Ziva and Isabella tracks the wearable response over 8 weeks.
Nutrition on GLP-1

Less appetite doesn't mean
nutrition takes care of itself

GLP-1 therapy dramatically reduces appetite - but eating less doesn't mean eating better. With significantly reduced caloric intake, nutrient density becomes critical: every meal needs to deliver maximum protein, vitamins, and minerals per calorie. Nutritional deficiencies are a real risk on GLP-1, particularly for protein, B12, iron, zinc, and magnesium. Ziva's Nutrition section tracks what matters.

Priority hierarchy on GLP-1
In order
1
Protein — hit your target first
1.6–2.2g per kg bodyweight. Eggs, chicken, fish, Greek yoghurt, legumes. Prioritise at every meal before carbohydrates.
2
Vegetables — maximum micronutrient density
With smaller total intake, every bite needs to deliver vitamins and minerals. Non-starchy vegetables at every meal.
3
Healthy fats — omega-3 priority
Oily fish, olive oil, avocado. Omega-3s reduce inflammation and support the cardiovascular benefit of GLP-1 therapy.
4
Carbohydrates — low-glycaemic, last
Wholegrains, legumes, root vegetables. Eat after protein and vegetables to reduce post-meal glucose impact.
Supplement priorities on GLP-1
Watch carefully
Vitamin B12 - particularly with Ozempic (semaglutide may affect B12 absorption); deficiency causes fatigue, nerve symptoms, and worsened HRV
Magnesium - reduced food intake increases deficiency risk; essential for sleep quality and HRV. Glycinate form best for sleep
Iron - particularly important for menstruating women; reduced food intake may not meet iron requirements
Creatine - 5g/day for lean mass preservation; one of the best-evidenced supplements during caloric restriction
Vitamin D - stored in fat tissue; as fat is mobilised on GLP-1, vitamin D status may shift; monitor and supplement
Electrolytes - nausea and reduced food intake can reduce sodium, potassium, and magnesium; fatigue and HRV suppression may signal electrolyte depletion
I
Isabella
GLP-1 nutrition insight
Attention needed
"Your protein log is averaging 72g/day against a target of 120g — this is below the threshold for lean mass preservation on your current weight loss rate. Your HRV improvement has plateaued over the past 2 weeks, which is consistent with muscle loss slowing the metabolic benefit. Increasing protein to 120g/day and adding a third resistance training session this week would likely break that plateau."
Exercise on GLP-1

Exercise is not optional
on GLP-1 - it's essential

GLP-1 therapy alone produces significant weight loss - but without exercise, a substantial portion of that loss is lean muscle mass. Adding resistance training to GLP-1 therapy consistently improves outcomes: better HRV, greater fat-to-muscle ratio of weight lost, higher long-term metabolic rate, and superior cardiovascular fitness improvement. The combination of GLP-1 and exercise is meaningfully better than either alone.

Resistance training
Non-negotiable — 2–3×/week
The primary tool for lean mass preservation. Compound movements - squat, deadlift, bench, row - stimulate the most muscle retention. Progressive overload matters: aim to increase resistance as strength improves. Each session produces an acute HRV boost and a 24–48 hour window of improved insulin sensitivity. Isabella tracks training days and correlates with next-day HRV.
Zone 2 cardio
Metabolic and cardiovascular
Moderate-intensity aerobic exercise (conversation-pace walking, cycling, swimming - 60–70% max heart rate) trains mitochondrial density and fat oxidation capacity, directly improving metabolic health alongside GLP-1's insulin-sensitising effects. 150 min/week is the evidence target. As body weight falls on GLP-1, the same Zone 2 effort produces greater fitness gains - Isabella tracks your improving heart rate response over time.
Managing reduced energy
Early weeks are harder
Nausea and reduced caloric intake during dose escalation can reduce energy for exercise. Isabella distinguishes genuine fatigue (low HRV, low recovery) from conditioned avoidance - and suggests the appropriate intensity for each day's readiness. On low-HRV days, walking and gentle movement are often more appropriate than intense training.
HRV-guided intensity on GLP-1
Isabella uses your daily HRV to recommend appropriate exercise intensity - flagging when HRV suppression (from nausea, dose escalation, or poor sleep) makes intense training counter-productive, and identifying the windows when higher-intensity resistance work is well-timed. This is particularly important in the dose escalation phase when physiological stress is higher and the capacity for training recovery is lower.
Managing Side Effects

Most side effects are manageable —
and wearable data helps

GLP-1 side effects are real but manageable. The most common are gastrointestinal - nausea, constipation, reflux - and are most pronounced during dose escalation. They typically resolve at each dose level within 2–4 weeks. Wearable data adds context: HRV and sleep disruptions during side effect peaks are expected, and Isabella contextualises them against the medium-term trajectory.

Nausea
Most common
Affects 40–50% of users during dose escalation. Typically worst at the new dose within the first 2 weeks, then improves. Eating smaller meals, protein-first, avoiding high-fat or spicy foods, and injecting in the evening reduces severity. Wearable HRV may suppress during nausea peaks - Isabella contextualises this as expected rather than concerning.
Constipation
Manageable
Slowed gastric motility on GLP-1 can cause constipation in 25–30% of users. Increasing water intake, fibre (psyllium, vegetables), and daily movement (walking) are the primary interventions. Magnesium glycinate (400mg evening) has both a laxative effect and improves sleep and HRV - addressing two issues simultaneously.
Fatigue
Transient
Fatigue in the first weeks is often multifactorial: reduced caloric intake, GI stress, electrolyte depletion, and sleep disruption. Isabella distinguishes dose-escalation fatigue (low HRV concurrent with new dose, resolving over 2 weeks) from sustained fatigue requiring clinical attention. Electrolyte supplementation and adequate protein often resolve it within days.
When to contact your prescriber
Important
Severe or persistent abdominal pain, vision changes, rapid heart rate that doesn't resolve, or HRV suppression persisting more than 3 weeks beyond a dose escalation should prompt a clinical conversation. Isabella flags HRV and recovery patterns that are outside the expected GLP-1 response range and recommends clinical review.
Side effect management — quick reference
Nausea
Small meals · protein first · evening injection · ginger tea · avoid fatty/spicy foods
Constipation
Hydration · psyllium fibre · daily walking · Magnesium glycinate 400mg/evening
Fatigue
Electrolytes · adequate protein · prioritise sleep · gentle movement rather than rest
Reflux
Smaller meals · avoid eating 3h before bed · elevate head of bed · avoid lying down after meals
Dose pacing — the HRV signal

Some prescribers will slow or pause dose escalation if side effects are severe. Isabella provides objective data to support this decision: persistent HRV suppression more than 3 weeks after a dose increase - without acute illness explanation - suggests the body hasn't fully adapted to the current dose. Sharing this pattern with your prescriber provides objective grounds for pacing the escalation schedule to your physiological tolerance rather than a calendar-based schedule.

How Ziva Tracks GLP-1 Response

Continuous monitoring between
every clinic appointment

GLP-1 therapy spans months to years. Clinic appointments are quarterly. Ziva fills the gap - tracking HRV, sleep, nutrition, exercise, and medication continuously, so you and your provider always have an up-to-date physiological picture.

HRV & cardiovascular
Daily
HRV and resting heart rate tracked continuously - showing the cardiovascular response to GLP-1 therapy in real time. The most sensitive early indicator that the medication is working at the physiological level.
Sleep architecture
Deep sleep & apnea
Deep sleep percentage and overnight respiratory rate variability tracked nightly - showing sleep apnea improvement as it occurs, weeks before the next sleep study.
Protein & nutrition
Daily target
Protein logged against your personalised target (1.6–2.2g/kg). Isabella flags when intake falls below muscle-preservation threshold and correlates protein with HRV trajectory.
Resistance training
Session tracking
Training sessions logged and correlated with HRV trajectory - showing the lean mass protection benefit in wearable data and flagging when frequency falls below muscle-preservation threshold.
Side effect log
Dose context
Log nausea, fatigue, and GI symptoms alongside dose changes. Isabella correlates side effects with HRV suppression - distinguishing expected dose-escalation effects from patterns warranting clinical attention.
Weight & body composition
Scale + scans
Weight logged daily and trended over time. Upload DEXA or InBody scan results and Isabella tracks lean mass vs. fat loss - flagging muscle loss before it shows up on the scale.
Labs to Monitor on GLP-1

What to test, when - and how
your wearable data adds context

GLP-1 therapy warrants proactive monitoring - for response, for side effects, and for nutritional adequacy. Upload your results to Ziva and Isabella places them in the context of your continuous HRV and sleep data.

HbA1c & fasting glucose
Primary metabolic response marker. HbA1c reflects 3-month average blood sugar - typically improving by 0.5–2.0% on GLP-1. Correlates directly with HRV improvement - falling HbA1c and rising HRV track together. Wearable HRV provides a real-time proxy between 3-monthly HbA1c measurements.
At 3 months · 6-monthly
Lipid panel
GLP-1 typically reduces triglycerides by 15–25% and modestly raises HDL. LDL changes vary. Improving lipid panel alongside rising HRV confirms the cardiovascular benefit pathway is active. Elevated triglycerides at baseline are a strong HRV suppressant - their reduction is one mechanism by which GLP-1 improves HRV.
At 3 months · 6-monthly
Vitamin B12, iron, vitamin D
Nutritional adequacy monitoring - all three can become deficient on GLP-1 through reduced intake. B12 deficiency causes fatigue and nerve symptoms. Iron deficiency suppresses energy and HRV. Vitamin D deficiency is common at baseline in people with obesity and can shift as fat is mobilised. Check at baseline and 3–6 months.
Baseline · 3–6 months
Liver enzymes (ALT, AST)
GLP-1 reduces hepatic fat significantly in people with fatty liver disease - liver enzymes typically improve within 12–24 weeks. Falling ALT alongside rising HRV confirms that the anti-inflammatory and metabolic benefits are active. Rarely, gallstone formation can occur with rapid weight loss - right-upper-quadrant pain warrants clinical evaluation.
Baseline · 6-monthly
hs-CRP (inflammation)
High-sensitivity CRP falls with GLP-1 therapy as visceral fat decreases and metabolic health improves. Falling hs-CRP is one of the key mechanisms driving HRV improvement - these two markers should track together. An elevated hs-CRP at baseline that isn't falling after 12 weeks may indicate a secondary inflammatory cause requiring clinical evaluation.
Baseline · 6-monthly
Ziva Lab Integration
Upload your GLP-1 monitoring results and Isabella places them in context: a falling HbA1c alongside 12 weeks of rising HRV tells a different - and more complete - story than either alone. Your prescriber sees the continuous trajectory, not just a point-in-time snapshot.
Science Deep Dive

Common questions, answered

01
Do I need to stay on GLP-1 drugs forever?
Most clinical evidence shows that weight regain occurs after stopping GLP-1 - on average 60–70% of lost weight is regained within 1–2 years of discontinuation without lifestyle modification. This is a consequence of the medication's mechanism: it suppresses appetite pharmacologically rather than re-training hunger signals permanently. However, the cardiovascular, metabolic, and wearable improvements made during therapy are substantially preserved if lifestyle habits established during treatment - resistance training, protein-first nutrition, consistent sleep - are maintained after stopping. Ziva tracks this: users who maintain high HRV, resistance training frequency, and protein targets after stopping GLP-1 show far better wearable trajectories than those who revert to baseline habits. The medication creates a window; the habits close it.
Long-termLifestyle
02
Is tirzepatide (Mounjaro/Zepbound) better than semaglutide?
Head-to-head trials show tirzepatide produces meaningfully greater weight loss - approximately 20–22% vs. 15% for semaglutide - with similar side effect profiles. The greater weight loss comes from its dual mechanism: tirzepatide activates both GLP-1 and GIP receptors, with GIP contributing additional appetite suppression and metabolic benefit. For wearable metrics, greater weight loss generally translates to greater HRV improvement, larger RHR reduction, and more significant sleep apnea improvement - though individual variation is large. The choice between them is a clinical decision based on insurance coverage, tolerability, specific metabolic goals, and cost. Both are meaningfully superior to older weight-loss medications.
SemaglutideTirzepatide
03
Can I use GLP-1 drugs if I don't have obesity - just want to lose 10–15 pounds?
Regulatory approval of Wegovy and Zepbound requires BMI ≥30, or ≥27 with at least one weight-related comorbidity (diabetes, hypertension, sleep apnea, cardiovascular disease). Use at lower BMI is off-label and most prescribers won't prescribe it outside these criteria. The risk-benefit calculation is also different: at lower BMI, the cardiovascular and metabolic risk that GLP-1's benefits offset are substantially smaller, and the lean mass loss risk remains significant. For people below the approved BMI threshold, lifestyle interventions targeting insulin sensitivity, resistance training, and sleep produce meaningful metabolic improvements - tracked continuously in Ziva - without pharmacological risk.
EligibilityClinical
04
How long before I see HRV improvement on GLP-1?
The first meaningful HRV improvements typically appear at 4–8 weeks - driven by the initial insulin sensitivity improvements and early blood pressure reduction. The most significant HRV gains come between weeks 6–16 as weight loss accelerates, sleep apnea burden reduces, and inflammation falls. By week 12, HRV improvements of 8–15 ms above baseline are typical in strong responders. The trajectory is not linear: HRV may temporarily suppress during nausea peaks at each dose escalation, then recover and improve further. Resistance training and protein adequacy significantly accelerate the HRV trajectory - users who maintain both show 30–40% larger HRV improvements at week 12 compared to those who don't.
HRVTimeline
FAQ

Frequently asked

Ziva Health

See your GLP-1 response
in your wearable data - every day

Log your medication, track your protein, train consistently, and sleep well. Isabella connects your HRV, sleep, nutrition, and exercise into one picture - showing you and your prescriber exactly what's changing and why.

Track my GLP-1 response Explore more guides